Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
Author:
Affiliation:
1. Curis Inc., 45 Moulton Street, Cambridge, Massachusetts 02138
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/jm901453q
Reference32 articles.
1. The HER family and cancer: emerging molecular mechanisms and therapeutic targets
2. ERBB receptors and cancer: the complexity of targeted inhibitors
3. Targeting the function of the HER2 oncogene in human cancer therapeutics
4. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
5. An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Cited by 253 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment;Bioorganic Chemistry;2024-10
2. Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy;Bioorganic Chemistry;2024-10
3. Heterocycles–Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years;ChemMedChem;2024-08-29
4. Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator;Medical Oncology;2024-03-05
5. Recent advances in multitarget-directed ligands via in silico drug discovery;Drug Discovery Today;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3